People | December 14, 2023
Moderna Chief Commercial Officer steps down, President to look over pipeline strategy
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Demonstrate significant bleed reduction in hemophilia A and B
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Subscribe To Our Newsletter & Stay Updated
